Beam Therapeutics (MEX:BEAM) Beneish M-Score: -0.50 (As of Jun. 26, 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
68 GF Score
Price MXN628.46
GF Value MXN541.64
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Beneish M-Score?

Beam Therapeutics MEX:BEAM 68 Beneish M-Score is -0.50 as of Jun. 26, 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 68/100 and a GF Value™ of MXN541.64 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 831 Biotechnology companies, Beam Therapeutics ranks worse than 81.83% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.5 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Beam Therapeutics's Beneish M-Score or its related term are showing as below:

MEX:BEAM' s Beneish M-Score Range Over the Past 10 Years
Min: -4.7   Med: -1.77   Max: 2852.75
Current: -0.5

During the past 9 years, the highest Beneish M-Score of Beam Therapeutics was 2852.75. The lowest was -4.70. And the median was -1.77.


Beam Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Beneish M-Score Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only 1,922.47 -4.70 2.28 -4.13 -1.33

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.06 -4.13 -4.34 -1.33 -0.50

MEX:BEAM vs DNLI, ORKA, DYN: Beneish M-Score Comparison

For the Biotechnology subindustry, Beam Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beam Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Beneish M-Score falls into.


MEX:BEAM
68GF Score
Beam Therapeutics Inc MEX:BEAM
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Beam Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 1.9033+0.892 * 2.3221+0.115 * 0.8955
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4237+4.679 * 0.026844-0.327 * 1.0741
=-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was MXN0 Mil.
Revenue was 572.322 + 2054.612 + 177.902 + 159.408 = MXN2,964 Mil.
Gross Profit was 572.322 + 2054.612 + 177.902 + 159.408 = MXN2,964 Mil.
Total Current Assets was MXN22,847 Mil.
Total Assets was MXN26,703 Mil.
Property, Plant and Equipment(Net PPE) was MXN3,596 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN409 Mil.
Selling, General, & Admin. Expense(SGA) was MXN2,198 Mil.
Total Current Liabilities was MXN1,345 Mil.
Long-Term Debt & Capital Lease Obligation was MXN4,256 Mil.
Net Income was -1700.808 + 4398.738 + -2067.905 + -1926.058 = MXN-1,296 Mil.
Non Operating Income was 54.639 + 4521.267 + 58.335 + 104.201 = MXN4,738 Mil.
Cash Flow from Operations was -2317.436 + -1499.677 + -1494.667 + -1439.492 = MXN-6,751 Mil.
Total Receivables was MXN0 Mil.
Revenue was 152.823 + 627.068 + 280.961 + 215.664 = MXN1,277 Mil.
Gross Profit was 152.823 + 627.068 + 280.961 + 215.664 = MXN1,277 Mil.
Total Current Assets was MXN25,524 Mil.
Total Assets was MXN30,011 Mil.
Property, Plant and Equipment(Net PPE) was MXN4,333 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN437 Mil.
Selling, General, & Admin. Expense(SGA) was MXN2,234 Mil.
Total Current Liabilities was MXN2,896 Mil.
Long-Term Debt & Capital Lease Obligation was MXN2,965 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 2964.244) / (0 / 1276.516)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1276.516 / 1276.516) / (2964.244 / 2964.244)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (22846.583 + 3595.63) / 26702.786) / (1 - (25523.937 + 4332.74) / 30010.543)
=0.009758 / 0.005127
=1.9033

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2964.244 / 1276.516
=2.3221

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(436.568 / (436.568 + 4332.74)) / (409.399 / (409.399 + 3595.63))
=0.091537 / 0.102221
=0.8955

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2198.311 / 2964.244) / (2234.165 / 1276.516)
=0.741609 / 1.750205
=0.4237

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4256.457 + 1344.608) / 26702.786) / ((2964.782 + 2895.776) / 30010.543)
=0.209756 / 0.195283
=1.0741

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1296.033 - 4738.442 - -6751.272) / 26702.786
=0.026844

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Beam Therapeutics has a M-score of -0.75 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.50 mean?
Beam Therapeutics (MEX:BEAM) has a Beneish M-Score of -0.50 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beam Therapeutics and its competitors. According to the industry distribution chart, Beam Therapeutics ranks #680 out of 831 companies in the Biotechnology industry, placing it in the top 81.8%.
Is Beam Therapeutics' Beneish M-Score too high?
Beam Therapeutics' current Beneish M-Score is -0.50. Based on the distribution chart, Beam Therapeutics ranks #680 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Beneish M-Score compare to DNLI and ORKA?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #680 out of 831 companies for Beneish M-Score. This places Beam Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Beneish M-Score is -0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN541.64, compared to a current price of MXN628.46 — trading 16% above its estimated fair value. The current Beneish M-Score is -0.50. Beam Therapeutics' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Beneish M-Score is -0.50 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 16% above its estimated GF Value™ of MXN541.64. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Beneish M-Score: -0.50
  • GF Value™: MXN541.64 vs. price of MXN628.46 (16% above fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score

Get the complete analysis for MEX:BEAM

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN541.64
GF Value